Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA
References
1. Eikelboom, JW, Connolly SJ, Bosch J, et al. N Engl J Med 2017; 377:1319-1330.
Review
For citations:
Press Release B. Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA. Rational Pharmacotherapy in Cardiology. 2018;14(5):797. (In Russ.)
Views:
508
Email this article 